Category Archives: – Pharma

The Biggest stories of 2015

December 31, 2015- by Steven E. Nike Roshe Run Femme Greer, MD 2015 was the year of ISIS. The radical jihadist group started the year with an attack in France,

Posted in - Biotech, - Generics, - Medical Devices, - Opinion, - Pharma, - Policy, - Reviews, books, devices, - The Weekly Summary | Leave a comment

Robert De Niro gives credibility to vaccine truthers

Update March 27, 2016- Less than 24-hours after our story, this film has been pulled from the lineup. It was our story that got the heads of

Posted in - Pharma, - Reviews, books, devices, CDC, FDA, NIH, Pediatrics, Primary care medicine | Leave a comment

Are the new PCSK9 cholesterol lowering drugs worth the high cost?

December 16, 2015- Interviewed by Steven E. Greer, MD

Posted in - Biotech, - NEJM, - Opinion, - Pharma, - Policy, Cardiology, CMS, FDA | Leave a comment

Martin Shkreli, CEO of Turing Pharmaceuticals, could be the Bernie Madoff of the drug industry

September 22, 2015- by Steven E. Greer, MD Making national news today was Martin Shkreli, the baby-faced, greasy-haired, disheveled-looking

Posted in - Biotech, - Pharma, Congress, FDA | Leave a comment

Rand Paul’s secret Looney Tune side revealed

http://youtu.be/AlWcDDZ1w38 February 2, 2015- By Steven E. Greer, MD People have asked me my opinion of the Republican field for 2016 and I have told them that Dr. Rand

Posted in - Pharma, Congress, Infectious disease, Pediatrics, Primary care medicine | Leave a comment

Using Afrezza inhaled insulin with a CGM

November 3, 2014- Interviewed by Steven E. Greer, MD Inhaled insulin will make a comeback when Mannkind’s drug, Afrezza, goes on sale in early 2015.

Posted in - Pharma, Diabetes and endocrinology, Primary care medicine, Univ Miami | Leave a comment

The FDA’s new Breakthrough status for new drug applications

May 24, 2013- Interviewed by Steven E. Greer, MD Janet Woodcock, MD,

Posted in - Pharma, FDA | Leave a comment

The serious adverse events caused by topical testoserone

March 1, 2014

Posted in - Pharma, Dermatology, Diabetes and endocrinology, FDA | Leave a comment

The FDA discusses Brilinta

February 4, 2014- The WSJ is reporting today on a Johns Hopkins doctor who filed a federal

Posted in - Pharma, Cardiology, FDA | Leave a comment

Alex Rodriguez’s PED schedule

January 12, 2014- By Steven E. Greer, MD CBS’s “60 Minutes” interviewed the man, Anthony Bosch, claiming to have been the pseudo-doctor

Posted in - Opinion, - Pharma, Congress, Diabetes and endocrinology | Leave a comment

CBS allows TV doctor to make egregious claims about statins

Can a “calculator” really tell doctors who should be on Lipitor? Nortin Hadler, MD: lack of evidence for widespread statin use The risk of diabetes associated with statin drugs “You’re telling me this now?” Why the news is suddenly critical … Continue reading

Posted in - Pharma, Cardiology, Cedars Sinai | Leave a comment

New therapies for hepatitis C

November 6, 2013- Interviewed by Steven E. Greer, MD In Part 1, Sammy Saab, MD, MPH, liver disease and GI doctor from UCLA, discusses the standard of care

Posted in - Biotech, - Pharma, Gastroenterology and liver, Infectious disease, UCLA | Leave a comment

Super rapid acting insulin and inhaled insulin

September 9, 2013- Interviewed by Steven E. Greer, MD Jay Skyler, MD, PhD, Deputy Director of the Diabetes Research Institute at The University

Posted in - Biotech, - Pharma, Diabetes and endocrinology, Univ Miami | Leave a comment

FDA reviews the safety of Januvia, Byetta, and other GLP-1 diabetes drugs

Interviewed by Steven E. Greer, MD

Posted in - Pharma, FDA | Leave a comment

anti-PD1 and anti-PD-L1 drugs treating NSCLC

March 26, 2013 Interviewed By Steven E. Greer, MD

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

The Damon Runyon Cancer Research Foundation panel

March 8, 2013  By Steven E. Greer, MD We interviewed three of the oncologists and industry executives who spoke at the Damon Runyon

Posted in - Biotech, - Pharma, Harvard, Oncology | Leave a comment

Paul Richardson, MD: Three-drug regimen for multiple myeloma

December 15, 2015 Dr. Paul Richardson of Harvard’s Dana-Farber Cancer Institute reviews the recent Lancet article

Posted in - Biotech, - Pharma, Harvard, Oncology | Leave a comment

Steven Cummings, MD: The denosumab FREEDOM trial

August 11, 2009- Dr. Steven Cummings, director of the San Francisco Coordinating Center and faculty of UCSF, and

Posted in - Biotech, - NEJM, - Pharma, Diabetes and endocrinology, Obstetrics and Gynecology, Orthopedic surgery, Primary care medicine, Radiology, Spine surgery, Sports medicine, UC San Francisco | Leave a comment

Sundeep Khosla, MD discusses Amgen’s Denosumab

August 11, 2009- Sundeep Khosla of the Mayo Clinic who authored the NEJM editorial on Amgen’s denosumab

Posted in - Biotech, - Pharma, Mayo Clinic | Leave a comment

TIMI 38 and prasugrel

March 3, 2008- by Steven E. Greer, MD One of the more important presentations at the upcoming American College of Cardiology

Posted in - Pharma, Cardiology | Leave a comment